Junshi Biotech announced that it recently received a “Notice of Acceptance” from the State Drug Administration, and that a supplementary application for treprilizumab combined chemotherapy for perioperative treatment of patients with resectable stage II to III non-small cell lung cancer has been accepted, and the scope of application indications has been expanded. The drug's development and approval are susceptible to uncertainties, and it is uncertain whether this supplementary application will be approved.

Junshi Biotech announced that it recently received a “Notice of Acceptance” from the State Drug Administration, and that a supplementary application for treprilizumab combined chemotherapy for perioperative treatment of patients with resectable stage II to III non-small cell lung cancer has been accepted, and the scope of application indications has been expanded. The drug's development and approval are susceptible to uncertainties, and it is uncertain whether this supplementary application will be approved.